Combined Oral Contraceptive Effects on Low-Grade Chronic Inflammatory Mediators in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Table 1

Characteristics of clinical studies comparing before and after changes in markers of chronic inflammation in PCOS patients with the use of different combined oral contraceptives.

Study	Country	Study design	N°	COC	Duration	PCOS
			patients	type and dose	months	diagnostic criteria
Morin-Papunen et al, 2003	Finland	Randomized open trial	10	EE 35 μg/ CPA 2 mg	06	NIH
Ibanez and de Zegher, 2004	Belgium/ Spain	Randomized open trial	16	EE 30 μg/ DRSP 3 mg	09	Rotterdam
Ibanez et al, 2005	Spain/ Belgium	Randomized open trial	21	EE 30 μg/ DRSP 3 mg	03	Rotterdam
Cagnacci et al, 2006	Italy	Randomized open trial	10	EE 35 μg/ CPA 2 mg	06	NIH
Cagnacci et al, 2006	Italy	Randomized open trial	10	EE 30 μg/ DSG 0.15 mg	06	NIH
Banaszewska et al, 2007	USA	Crossover open trial	24	EE 20 μg/ DSG 0.15 mg	03	Rotterdam
Gul et al, 2008	Turkey	Non-randomized open trial	30	EE 35 μg/ CPA 2 mg	03	Rotterdam
Hoeger et al, 2008	USA	Randomized open trial	11	EE 30 μg/ DSG 0.15 mg	06	NIH
Bilgir et al, 2009	Turkey	Randomized open trial	20	EE 35 μg/ CPA 2 mg	03	Rotterdam
Kebapcilar et al, 2010	Turkey	Randomized open trial	28	EE 35 μg/ CPA 2 mg	03	Rotterdam
Chen et al, 2010	Taiwan	Non-randomized open trial	56	EE 35 μg/ CPA 2 mg	03	Rotterdam
Mancini et al, 2010	Italy	Non-randomized open trial	28	EE 30μg/ DRSP 3 mg	06	Rotterdam
Teede et al, 2010	Australia	Randomized open trial	26	EE 35 μg/ CPA 2 mg	06	NIH
Tfayli et al, 2011	USA	Non-randomized open trial	20	EE 30 μg/ DRSP 3 mg	06	NIH
Essah et al, 2011	USA	Randomized open trial	10	EE 35 μg/ NGM 0.18-0.25 mg	03	Rotterdam
Kilic et al, 2011	Turkey	Randomized open trial	49	EE 30 μg/ DSG 0.15 mg	06	Rotterdam
Ibanez et al, 2011	Belgium/ Spain	Randomized open trial	17	EE 35 μg/ CPA 2 mg	06	NIH
Gode et al, 2011	Turkey	Non-randomized open trial	40	EE 35 μg/ CPA 2 mg	06	Rotterdam
Vieira et al, 2012	Brazil	Randomized open trial	21	EE 30 μg/ CMA 2 mg	12	Rotterdam
Diaz et al, 2012	Spain/ Belgium	Randomized open trial	14	EE 35 μg/ CPA 2 mg	12	NIH
Harmanci et al, 2013	Turkey	Non-randomized open trial	23	EE 30 μg/ DRSP 3 mg	06	Rotterdam
Ibanez et al, 2013	Spain/ Belgium	Randomized open trial	17	EE 35 μg/ CPA 2 mg	18	NIH
Christakou et al, 2014	Greece	Non-randomized open trial	40	EE 35 μg/ CPA 2 mg	06	NIH
Christakou et al, 2014	Greece	Non-randomized open trial	40	EE 30 μg/ DRSP 3 mg	06	NIH
Glintborg et al, 2014	Denmark	Randomized open trial	23	EE 30 μg/ DSG 0.15 mg	12	Rotterdam
Kahraman et al, 2014	Turkey	Randomized open trial	19	EE 35 μg/ CPA 2 mg	12	AES
Kahraman et al, 2014	Turkey	Randomized open trial	20	EE 30 μg/ DRSP 3 mg	12	Rotterdam
Dardzinska et al, 2014	Finland	Crossover open trial	42	EE 35 μg/ CPA 2 mg	04	Rotterdam
Yildzhan et al, 2015	Turkey	Randomized open trial	56	EE 30 μg/ DRSP 3 mg	06	Rotterdam
Yildzhan et al, 2015	Turkey	Randomized open trial	50	EE 30 μg/ CMA 2 mg	06	Rotterdam
Orio et al, 2016	Italy	Randomized double-blind trial	47	EE 35 μg/ CPA 2 mg	06	Rotterdam

a: not clearly stated.